Scholarlink

<p>As global efforts to eliminate cervical cancer grow, high-risk groups including haematopoietic stem cell transplant (HSCT) survivors must be prioritised. These individuals face increased risk of HPV-related cancers, making HPV testing, vaccination, and screening crucial. This cross-sectional observational study evaluated HPV vaccination rates, infection prevalence, and cervical cytology in HSCT survivors. Thirty female HSCT survivors (18–45 years) and 30 age-matched healthy controls were enrolled at a tertiary center in India. HPV vaccination history was recorded, cervical samples collected for cytology and HPV-DNA testing, and unvaccinated participants were advised HPV-vaccination. High-risk HPV-DNA was detected in 17% (5/30) of HSCT survivors (OR: 5.8; 95% CI: 0.63–54.1; <i>p</i>=0.09) versus one control. Abnormal cervical cytology was seen in 10% (3/30) of survivors (OR: 7.8; 95% CI: 0.38–157.1; <i>p</i>=0.119), with none in controls. These differences were not statistically significant, likely due to small sample size and limited statistical power. No associations were found between HPV positivity and age, immunosuppression, or cGVHD history. Vaccination rates remained low, with only two vaccinated before and ten after counselling, indicating limited awareness among HSCT survivors. HSCT survivors have higher risks of HPV infection and cervical abnormalities, underscoring the need for affordable HPV vaccine coverage.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

With the 90-70-90 Target for all, is the High-Risk Group HPV Vaccinated: A Peep into the Real-World Scenario Amongst Stem Cell Recipients

  • 期刊论文

  • 发表日期：

    2026年2月16日

查看全文
  • Riya Jain,
  • Aashima Arora,
  • Arihant Jain,
  • Nalini Gupta

摘要

As global efforts to eliminate cervical cancer grow, high-risk groups including haematopoietic stem cell transplant (HSCT) survivors must be prioritised. These individuals face increased risk of HPV-related cancers, making HPV testing, vaccination, and screening crucial. This cross-sectional observational study evaluated HPV vaccination rates, infection prevalence, and cervical cytology in HSCT survivors. Thirty female HSCT survivors (18–45 years) and 30 age-matched healthy controls were enrolled at a tertiary center in India. HPV vaccination history was recorded, cervical samples collected for cytology and HPV-DNA testing, and unvaccinated participants were advised HPV-vaccination. High-risk HPV-DNA was detected in 17% (5/30) of HSCT survivors (OR: 5.8; 95% CI: 0.63–54.1; p=0.09) versus one control. Abnormal cervical cytology was seen in 10% (3/30) of survivors (OR: 7.8; 95% CI: 0.38–157.1; p=0.119), with none in controls. These differences were not statistically significant, likely due to small sample size and limited statistical power. No associations were found between HPV positivity and age, immunosuppression, or cGVHD history. Vaccination rates remained low, with only two vaccinated before and ten after counselling, indicating limited awareness among HSCT survivors. HSCT survivors have higher risks of HPV infection and cervical abnormalities, underscoring the need for affordable HPV vaccine coverage.